People · Operator
Named in public records as an officer, director or promoter · active 2011–2021 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Phosplatin Therapeutics LLC | — | Pharmaceuticals | Series B | $72.3M | $722.8M | 2018 |
| Huldra Silver Inc. | — | Other | Seed | $5.0M | $14.1M | 2011 |
PETER ESPIG at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside PETER ESPIG on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Porter | 1 | 4 |
| Matthew Price | 1 | 4 |
| Neil Sunderland | 1 | 2 |
| Elizabeth Tallett | 1 | 2 |
| GARTH BRAUN | 1 | 1 |
| MAGNUS BRATLIEN | 1 | 1 |
| Fallon Robert | 1 | 1 |
| KATHLEEN NOSEK | 1 | 1 |
| Rosita Leong | 1 | 1 |
| Robert Fallon | 1 | 1 |
| John Caouette | 1 | 1 |
| Frances Bonham | 1 | 1 |
| Charles Stuckey | 1 | 1 |
| RYAN SHARP | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.